October 26-28 marks the third annual Clinical Pathways Congress. Leading experts convene in Boston, MA to dive in and address the operational questions raised by cancer center directors, clinical pathways directors, medical and pharmacy benefit managers, pathway vendors, and other stakeholders involved on pathway committees about design, development, implementation, utilization, and outcome measurement.
Ray D Page, DO, PhD, explained how pathways can serve as a mechanism to pressure drug pricing, assist in prior authorization burden, and provide system-wide cost savings.
Andrew York, PharmD, JD, of CMMI, provided and update on the role of quality improvement in oncology value-based payment, with specific attention to OCM Quality Measures.
Linda Bosserman, MD, FASCO, FACP, explains the importance of using decision support platforms that integrate care pathways and make use of collected data in real time to promote evidence-based patient care.
Incorporating Patient Experience, Financial Toxicity Into Clinical Pathways
Alan Balch, PhD, chief executive officer, National Patient Advocate Foundation, discussed the need to consider clinical pathways in helping differentiate options based on financial and logistical side effects that impact the patients’ care journey.
Bobby Daly, MD, MBA, and Robin Zon, MD, FACP, FASCO, outline the key elements for practices to consider in determining whether to buy or build their own pathways.
Winston Wong, PharmD, explained the findings of the first JCP clinical pathways benchmarking survey, including respondents’ reasons for pathway implementation, barriers to implementation, and potential for clinical pathways outside of oncology.
Clinical Pathways Congress 2018 Preview
Listen to Winston Wong, PharmD, summarize the key sessions and topics on the agenda at the 2018 Clinical Pathways Congress this October in Boston, MA.
ASCO Endorses Clinical Pathways Congress
JCP is the official journal of the Clinical Pathways Congress meeting.